Tech Company Financing Transactions
Cora Therapeutics Funding Round
Cora Therapeutics, operating out of Toronto, raised $1 million from Irongate Capital Advisors.
Transaction Overview
Company Name
Announced On
3/27/2023
Transaction Type
Venture Equity
Amount
$1,000,000
Round
Seed
Investors
Irongate Capital Advisors (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the launch of DNA HALO in North America. They will be targeting, medical professionals, medical imaging patients, air travel professionals, frequent fliers, military personnel, and the health-conscious public.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Undisclosed
Toronto, CA Undisclosed
USA
Toronto, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Cora Therapeutics is a company dedicated to delivering and supporting innovative research-based wellness solutions for whole body health, led by Dr Kieran Murphy. Dr. Murphy has lost colleagues to diseases that are linked to long-term occupational radiation exposure and, as a practicing physician himself, long recognized the need for better ways to counter radiation exposure. In 2011 he began developing an antioxidant formulation to help prevent cellular and mitochondrial damage from oxidative stress. The end result is Halo, the first product launched by Cora Therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Simpson
Founder
Kieran Murphy
Browse more venture capital transactions:
Prev: 3/27/2023: Cauldron Ferm venture capital transaction
Next: 3/27/2023: ArriVent Biopharma venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs